In new draft guidance, the
UK’s National Institute for Health
and Care Excellence (NICE) has
recommended bortezomib
(Velcade) as a treatment for some
patients with newly diagnosed
multiple myeloma.
Velcade is already available in
Australia as an authority script on
the PBS under specific conditions.
In other NICE news, draft guidance
has not recommended radium-223
dichloride (Xofigo, Bayer) for
relapsed prostate cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Mar 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.